Comparative Pharmacology
Head-to-head clinical analysis: ICLUSIG versus TASIGNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLUSIG versus TASIGNA.
ICLUSIG vs TASIGNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the activity of BCR-ABL, the constitutively activated fusion protein responsible for chronic myeloid leukemia (CML). It also inhibits other kinases including KIT, PDGFR, and DDR1.
45 mg orally once daily with or without food.
400 mg orally twice daily approximately every 12 hours. Administer on an empty stomach (no food for at least 2 hours before and 1 hour after dose). Swallow whole with water; do not crush or chew.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Terminal elimination half-life is approximately 90-120 hours, supporting once-daily dosing.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Primarily fecal (approximately 66-93% of the dose) as unchanged drug and metabolites; renal excretion is minimal (<5% of the dose).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor